Development of an ELISA with acidification treatment for an antibody conjugate incorporating Exatecans
Analytical Biochemistry · 2024
DOI: 10.1016/j.ab.2024.115530 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytical Biochemistry, 2024. Verfasst von Yingying Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunoassay and Immunochemistry, Center for Drug Safety Evaluation and Research, Shanghai Institute of Materia Medica, Chinese Academy …. Hauptthemen laut MEDLINE: Immunoconjugates, Antibodies, Monoclonal, Camptothecin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
The successful development of Sacituzumab Govitecan and Trastuzumab Deruxtecan has made camptothecin derivatives one of the most popular payloads for antibody-drug conjugates (ADCs). Camptothecin and its derivatives all exist in a pH-dependent equilibrium between the carboxylate and lactone forms. Such transformation may lead to differences in the ratio of the two molecular forms in calibration standards and biological matrix (bio-matrix) samples, thereby leading to inaccurate conjugated antibody results. In this study, we reported an enzyme-linked immunosorbent assay (ELISA) free of the aforementioned influence for the detection of the Exatecans-conjugated antibody (conjugated SM001) in cynomolgus monkey serum. The assay was developed by first acidifying all samples with glacial acetic acid (HAc), then performing neutralization and thereafter capturing conjugated SM001 with anti-Exatecan monoclonal antibody (mAb) and detecting it with biotinylated Nectin4 (hNectin4-Bio) and horseradish peroxidase-labeled streptavidin (SA-HRP). Results showed that all tested performance parameters met the acceptance criteria. The conjugated SM001 concentrations obtained were in parallel to but slightly lower than total antibody (TAb) throughout the pharmacokinetic (PK) study, revealing that the assay strategy implemented for conjugated SM001 measurement worked well for the elimination of interference triggered by the heterogeneous existence of the lactone and carboxylate forms of Exatecan (lactone-Exatecan and carboxylate-Exatecan).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunoassay and Immunochemistry, Center for Drug Safety Evaluation and Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Pudong, Shanghai, 201203, China; Nanjing University of Ch…
- Department of Immunoassay and Immunochemistry, Center for Drug Safety Evaluation and Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Pudong, Shanghai, 201203, China.
- Department of Immunoassay and Immunochemistry, Center for Drug Safety Evaluation and Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Pudong, Shanghai, 201203, China; State Key Laboratory of…
Zitieren
APA
Zhang, Y., Yun, X., Ouyang, L., Zhang, X., Gong, L., & Qin, Q. (2024). Development of an ELISA with acidification treatment for an antibody conjugate incorporating Exatecans. Analytical Biochemistry. https://doi.org/10.1016/j.ab.2024.115530
Vancouver
Zhang Y, Yun X, Ouyang L, Zhang X, Gong L, Qin Q. Development of an ELISA with acidification treatment for an antibody conjugate incorporating Exatecans. Analytical Biochemistry. 2024. doi:10.1016/j.ab.2024.115530
BibTeX
@article{Zhang2024,
author = {Zhang, Yingying and Yun, Xi and Ouyang, Lu and Zhang, Xianjing and Gong, Likun and Qin, Qiuping},
title = {Development of an ELISA with acidification treatment for an antibody conjugate incorporating Exatecans},
journal = {Analytical Biochemistry},
year = {2024},
doi = {10.1016/j.ab.2024.115530}
}
EUVIMED